<DOC>
	<DOCNO>NCT01470443</DOCNO>
	<brief_summary>The objective trial compare Progression free survival GEMOX ( gemcitabine/oxaliplatin ) v XELOX ( capecitabine/oxaliplatin ) metastatic unresectable Biliary tract carcinoma patient .</brief_summary>
	<brief_title>Study GEMOX ( Gemcitabine/Oxaliplatin ) Versus XELOX ( Xeloda/Oxaliplatin ) Advanced Biliary Tract Carcinoma</brief_title>
	<detailed_description>In patient advanced BTC ( biliary tract cancer ) , either gemcitabine-based , 5-FU-based chemotherapy clinical trial recommend first-line treatment . According ABC-02 trial , compare gemcitabine alone , cisplatin plus gemcitabine associate significant survival advantage without addition substantial toxicity . Cisplatin plus gemcitabine appropriate option treatment patient advance biliary cancer . ( ClinicalTrials.gov number , NCT00262769 . ) Recent metaanalysis [ 7 ] , analyze 104 phase II III trial comprise 2810 BTC patient find gemcitabine combine platinum compound cisplatin oxaliplatin superior response rate survival compare gemcitabine alone . The metaanalysis conclude combination gemcitabine cisplatin oxaliplatin reference arm future clinical trial . Meanwhile , oxaliplatin ( l-OHP ) , alkylating diaminocyclohexane platinum derivate , note display mark cytotoxic synergism combination fluoropyrimidines variety solid human tumour cell [ 11 ] . Based information , Nehls et al . [ 12 ] conduct prospective phase II study oxaliplatin plus 5-FU/folinic acid biliary system adenocarcinoma , disease control rate ( responses stable disease ( SD ) ) 56 % , median OS 9.5 month . To improve efficacy offer convenient treatment option patient reduce clinical visit avoid indwell device , prospectively investigated activity toxicity profile three-weekly intravenous oxaliplatin plus oral capecitabine ( XELOX ) , conclude XELOX regimen well-tolerated active treatment option advance BTC [ 13 ] . Given lack prospective , direct , comparison XELOX GEMOX regimens advanced BTC , propose randomized phase III trial GEMOX ( gemcitabine/oxaliplatin ) v XELOX ( capecitabine/oxaliplatin ) metastatic unresectable BTC patient .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Inclusion criterion 1. age ≥ 18 2. histologically cytologically confirm adenocarcinoma biliary tract ( intrahepatic , extrahepatic cholangiocarcinoma , gall bladder cancer.however , ampulla vater cancer exclude ) 3. unresectable metastatic 4 . ECOG performance status 0~2 5. measurable evaluable lesion per RECIST 1.1 criterion 6 . Life expectancy≥12weeks 7 . Adequate marrow , hepatic , renal cardiac function Serum aspartate transaminase serum alanine transaminase≤ 2.5 x upper limit normal ( ULN ) , AST ALT ≤ 5 x ULN liver function abnormality due underlie malignancy Total serum bilirubin ≤ 1.5 x ULN Absolute neutrophil count ( ANC ) ≥ 1,500/uL Platelets ≥ 100,0000/uL Hemoglobin ≥ 8.0 g/dL 8. chemotherapy naïve patient : prior adjuvant chemoradiation chemotherapy allow last date drug administration &gt; 6 month study entry date 9. provision sign write informed consent Exclusion criterion 1. severe comorbid illness and/or active infection 2. ampulla vater cancer exclude 3. pregnant lactate woman 4 . Active CNS metastasis controllable radiotherapy corticosteroid ( however , CNS metastases ( except leptomeningeal seed ) allow control gamma knife surgery surgery radiotherapy steroid ) 5. know history hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>